Clinical use of biomarkers in the era of Alzheimer's disease treatments
Open Access
- 30 December 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (1)
Abstract
With the advent of treatments that specifically target Alzheimer's disease brain pathology, biomarker tests will become an increasingly important part of the routine clinical evaluation of cognitive impairment and guide clinical decision making. Clinicians must ensure they are using accurate and well‐validated biomarker tests and select the most appropriate testing modality for each patient based on individual and practical considerations. The interpretation of test results may be complex and depends on the pre‐test probability and test‐specific factors. Biomarker results must be presented and discussed with patients in a process that is sensitive to the major implications of the results and is carefully connected to diagnosis, prognosis, and management. Advances in treatments for Alzheimer's disease will likely require non‐dementia specialists to use biomarkers, necessitating major educational efforts. In the new era of Alzheimer's disease treatments, biomarkers are essential tools that will be integrated into all aspects of dementia diagnosis and care.Keywords
Funding Information
- National Institute on Aging (K23AG073514, R01AG070941)
- Foundation for Barnes-Jewish Hospital
This publication has 49 references indexed in Scilit:
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Effect of Neprilysin Inhibition on Alzheimer Disease Plasma BiomarkersJAMA Neurology, 2024
- Quantitative Amyloid‐PET in Real‐World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) studyAlzheimer's & Dementia, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau RatiosJAMA Neurology, 2023
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer DiseaseJAMA Neurology, 2021
- Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or DementiaJAMA, 2019
- Assessment of Racial Disparities in Biomarkers for Alzheimer DiseaseJAMA Neurology, 2019
- Prevalence of Cerebral Amyloid Pathology in Persons Without DementiaJAMA, 2015